PMID- 27450634
OWN - NLM
STAT- MEDLINE
DCOM- 20170522
LR  - 20170522
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 43
IP  - 11
DP  - 2016 Nov
TI  - Effects of maxacalcitol ointment on skin lesions in patients with psoriasis
      receiving treatment with adalimumab.
PG  - 1354-1357
LID - 10.1111/1346-8138.13515 [doi]
AB  - Adalimumab is a biologic that is very effective for treatment of psoriasis.
      However, recalcitrant or recurrent lesions sometimes occur during treatment.
      Maxacalcitol is an active vitamin D3 ointment that is effective in treatment of
      psoriasis. Topical therapy may be beneficial in treatment of recalcitrant or
      recurrent lesions during treatment with systemic therapy, but there is little
      evidence on this topic. We investigated the effect of maxacalcitol on skin
      lesions during treatment with adalimumab in patients with psoriasis. Twelve
      patients with psoriasis were randomly assigned to two groups after informed
      consent - treatment with adalimumab only (n = 6), and treatment with adalimumab
      and maxacalcitol (n = 6) - and they were evaluated every 4 weeks for 44 weeks.
      Exacerbation was defined as an increase of the Psoriasis Area and Severity Index 
      (PASI) score. The interval between adalimumab treatments was elongated to 3-4
      weeks from 2 weeks according to the individual patient's condition. The PASI
      score was evaluated every 4 weeks, and the frequency of exacerbations was
      counted. The overall improvement in PASI score was not statistically different
      between the two groups, but the frequency of exacerbations was significantly less
      in the maxacalcitol combination group compared with the adalimumab monotherapy
      group (Mann-Whitney U-test, P < 0.05). The better control of skin lesions in
      patients who elongated the interval of adalimumab administration was achieved in 
      the maxacalcitol combination group compared with the adalimumab monotherapy
      group. Topical maxacalcitol treatment is effective and useful in controlling skin
      lesions in patients with psoriasis when used in combination with adalimumab.
CI  - (c) 2016 Japanese Dermatological Association.
FAU - Karakawa, Masaru
AU  - Karakawa M
AD  - Department of Dermatology, Jichi Medical University, Tochigi, Japan.
FAU - Komine, Mayumi
AU  - Komine M
AD  - Department of Dermatology, Jichi Medical University, Tochigi, Japan.
      mkomine12@jichi.ac.jp.
FAU - Kishimoto, Megumi
AU  - Kishimoto M
AD  - Department of Dermatology, Jichi Medical University, Tochigi, Japan.
FAU - Maki, Nobuki
AU  - Maki N
AD  - Department of Dermatology, Jichi Medical University, Tochigi, Japan.
FAU - Matsumoto, Ai
AU  - Matsumoto A
AD  - Department of Dermatology, Jichi Medical University, Tochigi, Japan.
FAU - Sugai, Junichi
AU  - Sugai J
AD  - Department of Dermatology, Jichi Medical University, Tochigi, Japan.
FAU - Ohtsuki, Mamitaro
AU  - Ohtsuki M
AD  - Department of Dermatology, Jichi Medical University, Tochigi, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20160723
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Ointments)
RN  - FXC9231JVH (Calcitriol)
RN  - FYS6T7F842 (Adalimumab)
RN  - N2UJM5NBF6 (maxacalcitol)
SB  - IM
MH  - Adalimumab/*therapeutic use
MH  - Adult
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Calcitriol/*analogs & derivatives/therapeutic use
MH  - Dermatologic Agents/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ointments
MH  - Psoriasis/*drug therapy
OTO - NOTNLM
OT  - *adalimumab
OT  - *additive effect
OT  - *combination therapy
OT  - *maxacalcitol
OT  - *psoriasis
EDAT- 2016/10/28 06:00
MHDA- 2017/05/23 06:00
CRDT- 2016/07/25 06:00
PHST- 2016/02/29 00:00 [received]
PHST- 2016/06/08 00:00 [accepted]
PHST- 2016/10/28 06:00 [pubmed]
PHST- 2017/05/23 06:00 [medline]
PHST- 2016/07/25 06:00 [entrez]
AID - 10.1111/1346-8138.13515 [doi]
PST - ppublish
SO  - J Dermatol. 2016 Nov;43(11):1354-1357. doi: 10.1111/1346-8138.13515. Epub 2016
      Jul 23.